Skip Navigation

Cardiovascular Research 2002 53(2):405-413; doi:10.1016/S0008-6363(01)00472-2
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bell, R. M
Right arrow Articles by Yellon, D. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bell, R. M
Right arrow Articles by Yellon, D. M
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Nitric oxide as a mediator of delayed pharmacological (A1 receptor triggered) preconditioning; is eNOS masquerading as iNOS?

Robert M Bell, Christopher C.T Smith and Derek M Yellon*

The Hatter Institute and Centre for Cardiology (Division of Medicine), University College London Medical School, Department of Cardiology, University College London Hospitals, Grafton Way, London WC1E 6DB, UK

* Corresponding author, The Hatter Institute for Cardiovascular Studies, Department of Academic Cardiology, University College Hospital, Gower Street, London WC1E 6AU, UK. Tel.: +44-20-7380-9888; fax: +44-20-7388-5095 hatter-institute{at}ucl.ac.uk

Background: Nitric oxide (NO), synthesised from the inducible isoform of nitric oxide synthase (iNOS), is implicated in mediating second window of protection (SWOP)/delayed ischemic preconditioning. However the role of NO and iNOS in delayed pharmacological protection remains unclear and is the subject of this investigation. Methods: To test the hypothesis that iNOS is necessary for delayed pharmacological preconditioning, the adenosine A1 receptor agonist, 2-chloro N6 cyclopentyl adenosine (CCPA) (25 µg/kg i.v.) or saline was administered to wild type (WT) or iNOS gene knockout mice (KO). Twenty-four hours later, the hearts were isolated, Langendorff perfused and subjected to 35 min ischemia/30 min reperfusion prior to infarct size determination. Results: WT and KO control hearts had identical infarct sizes of 37±3% and 37±2%, respectively. CCPA significantly reduced infarct size in WT hearts to 22±2% and also, unexpectedly, in KO hearts (27±2%). This protection was abrogated with the non-specific NOS inhibitor, N{omega} nitro L-arginine methyl ester (L-NAME, 100 µM), and could be mimicked in naïve hearts with the NO donor, donor S-nitroso N-acetyl DL penicillamine (SNAP, 1 µM). Delayed protection appeared to be mediated by NO synthesis in both WT and KO hearts. Additional studies using Western blot analysis demonstrated endothelial NOS (eNOS) upregulation and increased NOx release in both WT and KO hearts. Conclusions: This is the first study to demonstrate a role for eNOS in delayed A1 receptor triggered (pharmacological) preconditioning, potentially representing a new pharmacological target for protecting the ischemic heart.

KEYWORDS Adenosine; Nitric oxide; Infarction; Preconditioning


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ye, Y. Lin, S. Manickavasagam, J. R. Perez-Polo, B. C. Tieu, and Y. Birnbaum
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2436 - H2446.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ye, J. D. Martinez, R. J. Perez-Polo, Y. Lin, B. F. Uretsky, and Y. Birnbaum
The role of eNOS, iNOS, and NF-{kappa}B in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H343 - H351.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Merla, Y. Ye, Y. Lin, S. Manickavasagam, M.-H. Huang, R. J. Perez-Polo, B. F. Uretsky, and Y. Birnbaum
The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1918 - H1928.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. P. Taylor, M. E. Olsen, and J. W. Starnes
Improved postischemic function following acute exercise is not mediated by nitric oxide synthase in the rat heart
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H601 - H607.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Atar, Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, S. Rosanio, M.-H. Huang, B. F. Uretsky, J. R. Perez-Polo, and Y. Birnbaum
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1960 - H1968.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. Feron and J.-L. Balligand
Caveolins and the regulation of endothelial nitric oxide synthase in the heart
Cardiovasc Res, March 1, 2006; 69(4): 788 - 797.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Guo, A. B. Stein, W.-J. Wu, X. Zhu, W. Tan, Q. Li, and R. Bolli
Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and {delta}1-opioid receptor agonists is mediated by iNOS
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2251 - H2257.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. D. Lasley, B. J. Keith, G. Kristo, Y. Yoshimura, and R. M. Mentzer Jr.
Delayed adenosine A1 receptor preconditioning in rat myocardium is MAPK dependent but iNOS independent
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H785 - H791.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Z. Xu, S.-S. Park, R. A. Mueller, R. C. Bagnell, C. Patterson, and P. G. Boysen
Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes
Cardiovasc Res, March 1, 2005; 65(4): 803 - 812.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Birnbaum, Y. Ye, S. Rosanio, S. Tavackoli, Z.-Y. Hu, E. R. Schwarz, and B. F. Uretsky
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury
Cardiovasc Res, February 1, 2005; 65(2): 345 - 355.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Yamasowa, S. Shimizu, T. Inoue, M. Takaoka, and Y. Matsumura
Endothelial Nitric Oxide Contributes to the Renal Protective Effects of Ischemic Preconditioning
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 153 - 159.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Wang, C. Yin, L. Xi, and R. C. Kukreja
Opening of Ca2+-activated K+ channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2070 - H2077.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. Murphy
Primary and Secondary Signaling Pathways in Early Preconditioning That Converge on the Mitochondria to Produce Cardioprotection
Circ. Res., January 9, 2004; 94(1): 7 - 16.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. M. YELLON and J. M. DOWNEY
Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology
Physiol Rev, October 1, 2003; 83(4): 1113 - 1151.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Arnaud, D. Godin-Ribuot, S. Bottari, A. Peinnequin, M. Joyeux, P. Demenge, and C. Ribuot
iNOS is a mediator of the heat stress-induced preconditioning against myocardial infarction in vivo in the rat
Cardiovasc Res, April 1, 2003; 58(1): 118 - 125.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. M. Bell and D. M. Yellon
Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway
J. Am. Coll. Cardiol., February 5, 2003; 41(3): 508 - 515.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. M Bell, H. L Maddock, and D. M Yellon
The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart
Cardiovasc Res, February 1, 2003; 57(2): 405 - 415.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley
Myocardial Protection
Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438.
[Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.